BioNxt Solutions completes toxicity and pharmacokinetic studies for its ODF Cladribine product for multiple sclerosis treatment.
BioNxt Solutions Inc., a bioscience accelerator, has successfully completed toxicity and pharmacokinetic studies for its ODF Cladribine product for multiple sclerosis treatment. Advancing towards human comparative bioavailability studies, the company aims to obtain potential patent protection extending to 2044. Cladribine tablets are already approved for use in over 75 countries with a market size of approximately $41 billion by 2033.
March 18, 2024
3 Articles